| __timestamp | CymaBay Therapeutics, Inc. | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 8185000 | 31073000 |
| Thursday, January 1, 2015 | 8871000 | 43216000 |
| Friday, January 1, 2016 | 9645000 | 50679000 |
| Sunday, January 1, 2017 | 12387000 | 79171000 |
| Monday, January 1, 2018 | 14381000 | 168218000 |
| Tuesday, January 1, 2019 | 19238000 | 210796000 |
| Wednesday, January 1, 2020 | 17425000 | 203613000 |
| Friday, January 1, 2021 | 23040000 | 234273000 |
| Saturday, January 1, 2022 | 25116000 | 265784000 |
| Sunday, January 1, 2023 | 51953000 | 344501000 |
Unleashing insights
In the competitive landscape of biotechnology, managing operational costs is crucial. Over the past decade, Insmed Incorporated and CymaBay Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, peaking at $344 million in 2023. This reflects their aggressive expansion and investment in research and development. In contrast, CymaBay's expenses grew by approximately 535%, reaching $52 million in 2023. This indicates a more conservative growth strategy. The data highlights Insmed's commitment to scaling operations, while CymaBay maintains a steady, albeit slower, growth path. These trends offer insights into each company's strategic priorities and market positioning. As the biotech sector continues to evolve, understanding these financial dynamics is key for investors and industry analysts alike.
Novo Nordisk A/S and Insmed Incorporated: SG&A Spending Patterns Compared
Operational Costs Compared: SG&A Analysis of argenx SE and Insmed Incorporated
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs CymaBay Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Insmed Incorporated or Ascendis Pharma A/S
Operational Costs Compared: SG&A Analysis of Insmed Incorporated and Bio-Techne Corporation
Insmed Incorporated vs Lantheus Holdings, Inc.: SG&A Expense Trends
Who Optimizes SG&A Costs Better? Insmed Incorporated or Alkermes plc
Breaking Down SG&A Expenses: Insmed Incorporated vs PTC Therapeutics, Inc.
Insmed Incorporated vs Amphastar Pharmaceuticals, Inc.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for CymaBay Therapeutics, Inc. and Perrigo Company plc
Breaking Down SG&A Expenses: CymaBay Therapeutics, Inc. vs Wave Life Sciences Ltd.
SG&A Efficiency Analysis: Comparing CymaBay Therapeutics, Inc. and Taro Pharmaceutical Industries Ltd.